Mays Cancer Center at UT Health San Antonio | Strategic Alliance Partners

June 19, 2023

Comprehensive insight on acquired resistance to HER2-targeted therapy in metastatic breast cancer, and how treatments can be selected and sequenced thereafter.

June 12, 2023

Virginia Kaklamani, MD, DSc, shares her perspective on the roles that brain metastases and quality of life play, respectively, in selecting treatment for HER2+ mBC.

June 12, 2023

Focused discussion on factors that help inform treatment selection for patients with HER2+ metastatic breast cancer in the third-line setting.

June 05, 2023

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

June 05, 2023

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

March 16, 2023

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.

March 10, 2023

Virginia Kaklamani, MD, discusses the utilization of elacestrant following treatment with CDK4/6 inhibitors in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

March 09, 2023

Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.

March 09, 2023

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

March 07, 2023

Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.

March 02, 2023

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

March 02, 2023

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

February 28, 2023

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

February 28, 2023

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.

February 23, 2023

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

February 23, 2023

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

February 21, 2023

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

February 21, 2023

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

February 16, 2023

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

February 16, 2023

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.